recommendations. 1 An accompanying policy statement describes public policy recommendations. 2 
DEFINITIONS
• Tobacco product: any nicotine delivery product, currently regulated or unregulated by the US Food and Drug Administration (FDA), which is not approved for safe and effective tobacco dependence treatment.
• Secondhand smoke: the smoke emitted from a tobacco product that is inhaled by a nonuser. • Thirdhand smoke: the tobacco smoke that is absorbed onto surfaces and exposes the nonuser by either direct contact and dermal absorption and/or off-gassing and inhalation. Thirdhand smoke may react with oxidants and other compounds in the environment to yield secondary pollutants. 3 • Electronic nicotine delivery systems: handheld devices that produce an aerosol from a solution typically containing nicotine, flavoring chemicals, and carrier solvents such as propylene glycol and vegetable glycerin (glycerol) for inhalation by the user. Alternate names for these products include electronic cigarettes, e-cigarettes, e-cigs, electronic cigars, e-cigars, electronic hookah, e-hookah, hookah sticks, personal vaporizers, mechanical mods, vape pens, and vaping devices.
NEW INFORMATION
Tobacco smoke exposure in utero causes long-lasting neurocognitive, behavioral, and respiratory harms. Thirdhand smoke has become recognized as another route of tobacco toxin exposure. Noncigarette tobacco products represent emerging threats to children's health. Teenagers become dependent on nicotine far earlier than previously believed. Tobacco dependence can be treated using the chronic disease model, with treatment initiated on the basis of severity and adjusted on the basis of control.
BACKGROUND
More than half of children in the United States have evidence of tobacco exposure. 4 Tobacco-related carcinogens measured in house dust samples of smokers are at levels sufficient to increase cancer risk, 5 and young children may have greater exposure. The harm from tobacco smoke does not end when a smoker extinguishes a cigarette.
Tobacco causes respiratory illness, cancer, cardiovascular disease, and premature death in children and adults. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] In utero tobacco exposure increases risk of adverse fetal outcomes and can have long-lasting adverse health effects for the child. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Although sorting out in utero from postnatal effects is challenging, emerging data points to secondhand tobacco smoke exposure as an independent risk factor for neurobehavioral disorders (including attention-deficit/hyperactivity disorder, learning disabilities, and conduct disorders), 29-31 decreased glomerular filtration rate in adolescents, 32 and preclinical atherosclerosis in adolescents. 33, 34 There is no safe level of tobacco smoke exposure. 35 Parent and caregiver smoking are important sources of a child's tobacco smoke exposure. 36, 37 Parental tobacco dependence increases the risk of their children's tobacco use initiation and dependence. [38] [39] [40] Interventions to encourage parental tobacco cessation to benefit their children's health are most effective when the intervention includes pharmacotherapy. 41 Addressing and treating parent and caregiver tobacco dependence are important parts of children's health care.
Symptoms of tobacco dependence can develop rapidly after initiation of tobacco use. 42 The developing brains of children and adolescents are particularly susceptible to tobacco dependence. Nearly 90% of current smokers started tobacco use before their 18th birthday. 43 Adolescents from low-income families and lesbian/gay/bisexual/transgender youth shoulder a disproportionate share of the tobacco dependence burden. 44, 45 Alternative (other than cigarette) tobacco product use is rapidly gaining popularity among youth. 46 These include oral tobacco (chewing tobacco; moist snuff, also called "dip"), flavored cigars, pipes, snus (a moist tobacco product placed between the cheek and gum), hookahs (water pipes), and electronic nicotine delivery devices. Other tobacco products include bidis (tobacco wrapped in a tendu leaf), kreteks (tobacco flavored with cloves), 47 and dissolvable tobacco products (with appearance similar to breath mints or toothpicks). 48 Many adolescents use both cigarette and noncigarette tobacco products. 49 Pediatricians need to be aware of the different terminology that families may use for tobacco products. Because many families may not consider electronic nicotine delivery systems as "tobacco," questions may need to be modified to include "vape" or "vaping" and/or use of electronic cigarettes, hookah sticks, e-hookahs, and/or vape pens. Similarly, pediatricians may need to clarify what is being smoked because in some areas, marijuana smoking is also prevalent, and marijuana smoke/vapor contains many harmful, toxic, and carcinogenic chemicals.
RECOMMENDED ACTIONS FOR PEDIATRICIANS
Children can be exposed to tobacco smoke if they live in or are cared for near places where smoking is allowed, such as in multi-unit housing. 52 Pediatricians can help parents in advocating for a tobaccofree environment for their child.
Innovative approaches to screening include using an electronically administered questionnaire that, on the basis of patient responses, generates "just in time" prompts for the pediatrician. 53 Identifying adolescent tobacco use can be challenging. Screening questions can provide an opening for the pediatrician. Keep in mind that the tobacco product used might not be cigarettes.
Useful questions include the following 50 54 Messages should be clear, personally relevant, and age appropriate.
One of the most important things a child can do to prepare for a healthy life is not start using tobacco. Experimenting with tobacco use is not safe. Messages should start as early as children are developmentally ready to understand them, usually approximately 5 years of age.
Messages that may resonate more with adolescents include the effects of tobacco use on appearance, breath, and sports performance; lack of benefit for weight loss 43 ; how much money they would have to spend to continue their tobacco addiction; and how the tobacco industry deceives them. Other messages may include how fast tobacco dependence develops and the severity of tobacco addiction. The pediatrician should ask children and adolescents to make a commitment to be tobacco free and help them to identify their own reasons for being tobacco free.
Messages need to include a specific focus on electronic nicotine delivery systems. The vast majority of youth are regularly exposed to electronic nicotine delivery system advertising and promotion. 55 Most teens mistakenly believe that electronic nicotine delivery systems are safe, and many teens are not even aware that the devices contain nicotine or that nicotine is highly addictive. 56, 57 3. Address parent/caregiver tobacco dependence as part of pediatric health care.
Recommendation Strength: Strong Recommendation
Parental tobacco smoking is an important source of a child's tobacco smoke exposure, thus addressing parental and caregiver tobacco dependence is important to protect the health of the child.
3a. Recommend tobacco dependence treatment of tobacco-dependent parents and caregivers.
The US Public Health Service-sponsored evidence-based guideline "Treating Tobacco Use and Dependence: 2008
Update" recommends that "Counseling and medication are effective when used by themselves for treating tobacco dependence. The combination of counseling and medication, however, is more effective than either alone. Thus, clinicians should encourage all adults making an attempt to stop tobacco to use both counseling and medication. " 58 3b. Implement systems to identify and offer counseling, treatment, treatment recommendations, and/or referral for tobacco-dependent parents.
Recommendation Strength: Recommendation
In the context of protecting their children's health, parents should be encouraged to stop smoking and should be offered tobacco dependence treatment, treatment recommendations, and/or referral. Specific and personally relevant information about how their tobacco dependence affects their children's health should be offered. Most parents expect physicians to address tobacco dependence and value receiving information about treatment from their children's pediatrician. 59 Parents may be motivated to accept tobacco dependence treatment to benefit the health of their children as well as their own health. 41 Even brief advice can increase smoking cessation rates. 60 Recommendations should be appropriate to the parent's readiness to change. If a parent is not yet ready for tobacco dependence treatment, smoke-free policies for the home and car should be advised.
The Clinical Effort Against Secondhand Smoke Exposure (CEASE) program is a practical program for addressing parental tobacco dependence treatment that can be easily implemented in the pediatrician's office. CEASE focuses on the principles of ask ("Does your child live with anyone who uses tobacco?"), assist ("As your child's pediatrician [or nurse], I can help you quit tobacco and help you have a tobacco-free home and car"), and refer (refer to the national smokers' quitline: 1-800-QUIT-NOW). 61 CEASE program materials are available at http://www.ceasetobacco.org.
Tobacco dependence is not simply a bad habit; it is often a severe addiction. Nicotine causes changes to brain structure and chemistry such that it is difficult to feel normal without it. 62 Severity of nicotine withdrawal can vary from "wanting" (a mild desire to smoke that is short lived and easily ignored) to "craving" (a stronger urge to smoke that is more persistent and difficult to ignore) or "needing" (an intense and urgent desire to smoke that is unpleasant and unremitting). 63 Similar to the principles of control of other severe chronic illnesses, the disease severity guides initiation of pharmacotherapy, and disease control guides adjustment of therapy. The risk of relapse to smoking is minimized when there are minimal to no withdrawal symptoms. 50 Pharmacotherapy for tobacco dependence includes the long-acting nicotine patch (available over the counter) as well as bupropion and varenicline (which require a prescription). Shorter-acting medications can be used as needed for relief of nicotine withdrawal symptoms or as premedication before situations or events that trigger smoking. These medications include nicotine gum and lozenges (over the counter), nicotine inhaler (prescription), and nicotine nasal spray (prescription). The combination of 2 or more of these medications is more effective than 1 medication alone. 58 Combination therapy is particularly useful for those with moderate or severe levels of tobacco dependence. 50 Combination therapy with the nicotine patch (daily) and nicotine gum or lozenge (ad libitum) has similar effectiveness to the prescription agent varenicline 58 and can be recommended for those with moderate or severe tobacco dependence. 50 Starting nicotine replacement before stopping smoking can help a person to reduce smoking and get ready to stop. 64, 65 Use of pharmacotherapy substantially improves rates of stopping smoking. 58 
Recommendation Strength: Option
Treatment should be appropriate to the adolescent's level of tobacco dependence, readiness to change, and treatments he or she is ready to accept. Research on the treatment of adolescent tobacco dependence is limited. Behaviorally based programs are beneficial; however, they work best for those with minimal to mild tobacco dependence. 66 Effective behaviorally based strategies have focused on problem-solving skills and providing support and encouragement. 58 The "5 As" model (Ask, Advise, Assess, Assist, Arrange follow-up) describes a counseling intervention that improves tobacco use cessation rates in adults and is recommended by US Public Health Service Clinical Practice Guidelines. 58 An adaptation of this model for youth 67 Research on pharmacotherapy of moderate to severe adolescent tobacco dependence is limited by short courses of treatment, high rates of nonadherence, and high rates of relapse after discontinuation of therapy. [68] [69] [70] [71] Given the severe harms of tobacco dependence and the documented effectiveness of tobacco dependence pharmacotherapy in adults, a tobacco-dependent adolescent who wants treatment can be offered pharmacotherapy (medications that are FDA-approved as effective for tobacco dependence treatment in adults) appropriate to the severity of his or her tobacco dependence and his or her readiness to change as part of a tobacco dependence treatment plan.
As with treatment of any severe chronic illness, patients should be monitored for adverse effects of therapy, adherence to medication use recommendations, and achievement of treatment goals. Given the high rates of nonadherence to therapy and high rates of relapse of tobacco use among adolescents, close follow-up is recommended.
Pediatricians should also be aware that comorbidities of substance abuse and psychiatric disorders may accompany tobacco dependence 72 and may make tobacco dependence more difficult to treat. These comorbidities, when identified, should be addressed through appropriate referral.
In the United States, tobacco dependence treatment medications have not been approved by the FDA for use by people younger than 18 years. There is, however, no biological or cognitive rationale to have 18 years as the cutoff for offering effective pharmacotherapy of tobacco dependence. To legally obtain any FDA-approved tobacco dependence treatment product (including the over-the-counter products), an adolescent needs a prescription from a licensed health care provider.
Offer tobacco-dependent individuals quitline referral. Recommendation Strength: Strong Recommendation
Free (to the user) telephonic tobacco dependence treatment is beneficial and has been shown to improve tobacco cessation rates. 73 Such support is available at 1-800-QUIT-NOW in the United States.
SmokefreeTXT (to enroll, text the word QUIT to 47848 from a mobile phone) may be useful for those who prefer a text message-based intervention.
6. Consider potential for neuropsychiatric symptoms with tobacco dependence treatment.
Recommendation Strength: Recommendation
There is an increased risk of suicidal ideation and suicide both among continuing smokers and among those being treated for tobacco dependence. [74] [75] [76] [77] [78] In postmarketing surveillance, suicidal ideation and suicide have been reported among patients taking varenicline and bupropion, with a Black Box warning issued by the FDA for both medications. 79 Population-based studies suggest that rates of fatal and nonfatal self-harm are not different among adults who received varenicline, bupropion, or nicotine replacement. 80 Neuropsychiatric symptoms associated with tobacco dependence treatment may reflect inadequate control of nicotine withdrawal. 50 7. Do not recommend electronic nicotine delivery systems for tobacco dependence treatment.
Recommendation Strength: Strong Recommendation
Electronic nicotine delivery systems are not FDA-approved for tobacco dependence treatment and have not been shown to be safe or effective for tobacco dependence treatment. 81 One randomized controlled clinical trial of electronic cigarettes found low rates of stopping smoking with no significant difference between nicotine-containing and placebo devices in smoking cessation rates. 82 Among adolescents, the use of electronic cigarettes is associated with decreased rates of smoking cessation. 83 There is currently no regulation on content or manufacturing standards for electronic nicotine delivery systems. Carcinogens, toxicants, metals, and silicates have been found in the emissions from these devices. [84] [85] [86] They can expose nonusers to the nicotine and other toxicants in the device emissions. 81 Some of the commonly used flavoring chemicals are known respiratory irritants. 87 These products are being aggressively marketed to youth. 88 Flavorings, including candy and fruit flavors, increase the appeal to youth. The concentrated nicotine solution used in these devices is a poisoning risk for young children, with 1 child already known to have died of its accidental ingestion. 89, 90 8. If the sources of a child's tobacco smoke exposure cannot be eliminated, provide counseling about strategies to reduce the child's tobacco smoke exposure. 
